NASDAQ:HSKA - Heska Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $131.13
  • Forecasted Upside: 2.85 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$127.49
▲ +1.14 (0.90%)
1 month | 3 months | 12 months
Get New Heska Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HSKA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HSKA

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$131.13
▲ +2.85% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Heska in the last 3 months. The average price target is $131.13, with a high forecast of $163.50 and a low forecast of $59.00. The average price target represents a 2.85% upside from the last price of $127.49.
Buy
The current consensus among 4 investment analysts is to buy stock in Heska. This rating has held steady since February 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
6/8/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
9/6/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 0 sell ratings
12/5/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/4/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/2/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
8/31/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/30/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/29/2020

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/23/2020Piper SandlerBoost Price TargetOverweight$150.00 ➝ $157.00Medium
i
11/19/2020Raymond JamesBoost Price TargetOutperform$140.00 ➝ $145.00High
i
11/4/2020Alliance Global PartnersBoost Price TargetBuy$116.50 ➝ $163.50High
i
10/21/2020Raymond JamesUpgradeMarket Perform ➝ Outperform$125.00High
i
8/5/2020Alliance Global PartnersBoost Price TargetBuy$90.00 ➝ $116.50Medium
i
8/5/2020Piper SandlerUpgradeNeutral ➝ Overweight$87.00 ➝ $110.00High
i
5/25/2020Piper SandlerLower Price Target$107.00 ➝ $87.00Medium
i
5/8/2020Alliance Global PartnersBoost Price Target$78.00 ➝ $90.00High
i
4/3/2020Alliance Global PartnersLower Price TargetAverage ➝ Buy$137.00 ➝ $78.00Low
i
3/27/2020SidotiLower Price TargetNeutral$77.00 ➝ $59.00High
i
1/22/2020Piper SandlerBoost Price TargetNeutral$86.00 ➝ $107.00Low
i
1/15/2020SidotiBoost Price TargetNeutral$72.00 ➝ $77.00High
i
11/7/2019Raymond JamesDowngradeOutperform ➝ Market PerformMedium
i
11/6/2019Canaccord GenuityReiterated RatingBuy$75.00 ➝ $105.00High
i
9/18/2019Piper Jaffray CompaniesInitiated CoverageNeutral$68.00Low
i
9/12/2019Canaccord GenuityLower Price TargetBuy$95.00 ➝ $75.00High
i
7/1/2019Canaccord GenuityReiterated RatingBuy$95.00Low
i
5/23/2019GuggenheimInitiated CoverageNeutral ➝ NeutralHigh
i
2/27/2019B. RileyLower Price TargetNeutral ➝ Neutral$93.00 ➝ $87.00High
i
2/27/2019BenchmarkDowngradeBuy ➝ HoldLow
i
2/26/2019SidotiDowngradeBuy ➝ NeutralLow
i
2/20/2019Canaccord GenuityReiterated RatingBuy$118.00Low
i
7/19/2018BenchmarkInitiated CoverageBuy$120.00Medium
i
Rating by Raymond Myers at Benchmark Co.
6/15/2018Canaccord GenuityReiterated RatingBuy ➝ Buy$115.00 ➝ $123.00Low
i
5/31/2018Canaccord GenuityReiterated RatingBuy$100.00 ➝ $115.00Medium
i
5/21/2018BenchmarkBoost Price TargetBuy$120.00 ➝ $143.00Low
i
5/18/2018Canaccord GenuityReiterated RatingBuy$100.00 ➝ $115.00Low
i
5/18/2018B. RileyBoost Price TargetNeutral$77.00 ➝ $93.00Low
i
Rating by Kara Anderson at B. Riley
5/7/2018BenchmarkBoost Price TargetBuy ➝ Buy$90.00 ➝ $100.00Medium
i
5/7/2018Canaccord GenuityReiterated RatingBuy$95.00Medium
i
3/1/2018Canaccord GenuityReiterated RatingBuy$95.00High
i
3/1/2018B. RileyLower Price TargetNeutral ➝ Neutral$93.00 ➝ $77.00High
i
Rating by Kara Anderson at B. Riley
2/26/2018B. RileySet Price TargetHold$93.00Medium
i
Rating by Kara Anderson at B. Riley
2/5/2018SidotiUpgradeNeutral ➝ Buy$94.00Low
i
12/19/2017AegisReiterated RatingBuyLow
i
Rating by B. Haynor at Aegis
12/4/2017Raymond JamesReiterated RatingBuyHigh
i
11/3/2017B. RileyLower Price TargetNeutral ➝ Neutral$96.50 ➝ $93.00N/A
i
10/27/2017B. RileyReiterated RatingHold$96.50N/A
i
10/5/2017Canaccord GenuityInitiated CoverageBuy$115.00N/A
i
8/9/2017BenchmarkReiterated RatingBuy$106.00 ➝ $120.00High
i
Rating by Raymond Myers at Benchmark Co.
8/3/2017B. RileyReiterated RatingNeutral$96.50Medium
i
8/3/2017BenchmarkBoost Price TargetBuy ➝ Buy$106.00 ➝ $120.00Low
i
Rating by Raymond Myers at Benchmark Co.
8/1/2017AegisBoost Price TargetBuy$114.50 ➝ $129.50Low
i
7/28/2017B. RileyReiterated RatingNeutral$85.00Low
i
6/1/2017AegisInitiated CoverageBuy$114.50Medium
i
5/8/2017B. RileyReiterated RatingNeutral$85.00Medium
i
5/3/2017B. RileyReiterated RatingNeutral$85.00Medium
i
4/28/2017B. RileyReiterated RatingNeutral$83.00High
i
3/6/2017B. RileyReiterated RatingNeutral$83.00N/A
i
Rating by kara anderson at B. Riley
3/1/2017B. RileyReiterated RatingNeutral$83.00N/A
i
Rating by kara anderson at B. Riley
3/1/2017BenchmarkReiterated RatingBuy ➝ Buy$100.00 ➝ $106.00N/A
i
Rating by Raymond Myers at Benchmark Co.
2/23/2017B. RileyReiterated RatingNeutral$70.50N/A
i
Rating by kara anderson at B. Riley
2/6/2017BenchmarkBoost Price TargetHold$78.00 ➝ $100.00N/A
i
Rating by Raymond Myers at Benchmark Co.
1/26/2017CL KingDowngradeBuy ➝ NeutralN/A
i
11/29/2016BenchmarkInitiated CoverageBuy$78.00N/A
i
11/28/2016SidotiDowngradeBuy ➝ Neutral$71.00N/A
i
Rating by James Sidoti at Sidoti
11/22/2016SidotiDowngradeBuy ➝ Neutral$71.00N/A
i
11/7/2016B. RileyReiterated RatingNeutral$55.50N/A
i
Rating by kara anderson at B. Riley
11/2/2016B. RileyReiterated RatingNeutral$53.00N/A
i
Rating by kara anderson at B. Riley
10/28/2016B. RileyReiterated RatingNeutral$53.00N/A
i
Rating by kara anderson at B. Riley
9/26/2016B. RileyDowngradeNeutral$53.00N/A
i
Rating by kara anderson at B. Riley
9/21/2016B. RileyDowngradeBuy ➝ Neutral$52.50 ➝ $53.00N/A
i
Rating by K. Anderson at B. Riley
8/6/2016B. RileyReiterated RatingBuy$52.50N/A
i
Rating by Ian Corydon at B. Riley
8/4/2016GabelliDowngradeBuy ➝ HoldN/A
i
Rating by J. Tsai at Gabelli
8/1/2016B. RileyReiterated RatingBuy$42.50N/A
i
Rating by Ian Corydon at B. Riley
7/1/2016SidotiInitiated CoverageBuy$49.00N/A
i
5/9/2016B. RileyReiterated RatingBuy$42.50N/A
i
Rating by Ian Corydon at B. Riley
5/4/2016B. RileyReiterated RatingBuy$42.50N/A
i
Rating by Ian Corydon at B. Riley
4/28/2016B. RileyReiterated RatingBuy$41.50N/A
i
Rating by Ian Corydon at B. Riley
4/1/2016CL KingInitiated CoverageBuyN/A
i
3/11/2016B. RileyReiterated RatingBuy$41.50N/A
i
Rating by Ian Corydon at B. Riley
3/6/2016B. RileyReiterated RatingNeutral$33.25N/A
i
Rating by Ian Corydon at B. Riley
3/4/2016B. RileyUpgradeNeutral ➝ Buy$41.50N/A
i
Rating by Ian Corydon at B. Riley
3/1/2016B. RileyReiterated RatingNeutral$33.25N/A
i
Rating by Ian Corydon at B. Riley
(Data available from 11/29/2015 forward)
Heska logo
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps. It also provides digital radiography hardware and mobile digital radiography products, as well as ultrasound systems; Cloudbank, a Web-based image storage solution; ViewCloud and HeskaView, a picture archival and communications system for Cloudbank; point-of-care heartworm diagnostic test products for dogs and cats; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and treatment and control of ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops. The company's Other Vaccines and Pharmaceuticals segment offers a line of bovine vaccines; biological and pharmaceutical products for other animal health companies; and various turnkey services comprising research, licensing, production, labeling, and packaging, as well as provides validation support and distribution services. It sells its products to veterinarians through a field organization, a telephone sales force, and third party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. Heska Corporation was founded in 1988 and is based in Loveland, Colorado.
Read More

Today's Range

Now: $127.49
$125.62
$128.39

50 Day Range

MA: $118.03
$103.74
$129.18

52 Week Range

Now: $127.49
$50.00
$140.00

Volume

37,401 shs

Average Volume

68,081 shs

Market Capitalization

$1.21 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.7